Hudson Pacific PropertiesNYSE: HPP

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in the discovery and development of engineered B Cell Medicines (BCMs), today announced key milestones alongside a new round of funding as its lead program, BE-101 for Hemophilia B, enters the clinic, and its second development candidate for Hypophosphatasia is unveiled. Both programs are built on Be Bio's powerful and efficient BCM platform, which utilizes gene editing to engineer B cells to produce sus.

Hudson Pacific Properties (HPP) came out with quarterly funds from operations (FFO) of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $0.24 per share a year ago.

Investors need to pay close attention to Hudson Pacific (HPP) stock based on the movements in the options market lately.

Although the financial results of Hudson Pacific (HPP) for the quarter ending in March 2024 provide an overview of the company's performance, it may be beneficial to analyze how certain key metrics stack up against Wall Street projections and figures from the same period last year.

Hudson Pacific Properties has reinstated its suspended quarterly cash dividend. The REIT conducted $1 billion in asset sales in 2023 as higher office vacancies continue to pressure FFO. The leases for a third of HPP's office rent base come up for renewal over the next two years, with rents set to drop dramatically.

Hudson Pacific missed FFO estimates in Q4 amid a bevy of industry headwinds. The company also issued light forward FFO guidance.

Hudson Pacific Properties, Inc. (HPP) Q4 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Hudson Pacific (HPP) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Hudson Pacific Properties (HPP) came out with quarterly funds from operations (FFO) of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to FFO of $0.49 per share a year ago.